Research Article

Hysterosalpingography with Oil-Soluble Contrast Medium Does Not Increase Newborn Hypothyroidism

Divya M. Mathews, Jane M. Peart, Neil P. Johnson, Robert G. Sim, Natasha L. Heather, Dianne Webster, Susannah O’Sullivan, and Paul L. Hofman

1 Liggins Institute, University of Auckland, Auckland, New Zealand
2 Paediatric Endocrinology, Starship Children’s Hospital, Auckland, New Zealand
3 Auckland Radiology Group, Auckland, New Zealand
4 Repromed Auckland, Auckland, New Zealand
5 University of Auckland, Auckland, New Zealand
6 Robinson Research Institute, University of Adelaide, Adelaide, Australia
7 Newborn Metabolic Screening Programme, LabPlus, Auckland District Health Board, Auckland, New Zealand
8 Endocrinology, Greenlane Clinical Centre, Auckland District Health Board, Auckland, New Zealand

Correspondence should be addressed to Divya M. Mathews; d.mathews@auckland.ac.nz

Received 18 October 2021; Accepted 29 January 2022; Published 22 February 2022

Objective. Hysterosalpingography (HSG) with oil-soluble contrast medium (OSCM) improves pregnancy rates in women with idiopathic infertility. However, OSCM has high iodine content and slow clearance resulting in potential iodine excess. If pregnancy occurs, this could impact fetal thyroid gland development and function. We aim to determine the effect of a preconceptional OSCM HSG on the thyroid function of the neonate.

Results. Of 146 babies included, all had normal TSH levels with values ranging from 1 to 7 mIU/L on the whole blood analysis of a capillary heel sample using the Perkin–Elmer AutoDelfia assay. Conception during the first 3 cycles following an OSCM HSG was 76%; however, TSH levels in this group were not higher than those conceived in later cycles.

Conclusion. Preconceptional OSCM HSG did not increase the risk of congenital hypothyroidism in the New Zealand scenario.

1. Introduction

Congenital hypothyroidism (CH) is a preventable cause of intellectual disability. Routine newborn screening is recommended [1] and widely employed by most countries because it enables early detection of CH and initiation of thyroid hormone replacement therapy and thereby perseveration of normal intellectual and cognitive function [1–3]. Although the most common causes of congenital hypothyroidism are dysgenesis and dyshormonogenesis [4], maternal iodine excess can cause prolonged primary hypothyroidism in the offspring [5]. The recommended daily allowance (RDA) for iodine intake established by the Australian National Health and Medical Research Council (NHMRC) is 150 μg/day in adults and 220 μg/day in pregnant women [6]. The likely mechanism of thyroid dysfunction with iodine excess is fetal iodine exposure and a prolonged Wolff–Chaikoff effect causing suppression of fetal thyroid hormone release [7]. Newborn thyroid function is well described with maternal iodine excess, particularly with the use of amiodarone.
(75000 μg iodine/tablet) in the last trimester of pregnancy [8–12], faulty formulations of prenatal supplements, and dietary iodine excess intake or topical iodine [13–17].

Hysterosalpingography (HSG) using oil-soluble contrast medium (OSCM) is increasingly employed in infertile women as they improve fertility with at least a doubling of pregnancy rates when compared to no intervention [18, 19] and higher rates when compared to water-soluble contrast media (WSCM) (39.7% vs. 29.1%, respectively, in the H20I study) [20]. OSCM has a very high iodine content (480 mg iodine/ml of Lipiodol (Guerbet, France) and slow clearance with a half-life of 50 days [21]. Consequently, OSCM HSG is known to cause a 100-fold rise in iodine levels which fall slowly over the next six months to one year [22]. The fertility enhancement from OSCM is also maximal in the initial six months following the HSG [23]. Thus, the fetus conceived is at a risk of severe iodine exposure and subsequent problems with thyroid gland function.

Thyroid safety of children conceived following OSCM HSG in the context of potential iodine excess remains unclear [24]. A Japanese study suggested an increased incidence of newborn thyroid dysfunction in offspring conceived immediately following an OSCM HSG [25]. The incidence of thyroid-stimulating hormone (TSH) elevation was 2.4% (5/212 screened) and overt hypothyroidism was 0.94% (2/212 screened) as against 0.07% [26], the background rate of congenital hypothyroidism in the Japanese population. Interestingly, two of the five neonates with thyroid dysfunction had >20 ml OSCM (compared to a standard technique of <10 ml [27]) instilled in their mothers during the HSG and in three of the cases, the HSG to conception gap was less than two months suggesting that greater iodine exposure could be a risk factor for developing neonatal thyroid dysfunction. However, this pattern of increased thyroid dysfunction in newborns was not replicated in a later study in the Netherlands [28] or China [29].

Our research was conducted to determine the effect of preconceptional OSCM HSG on the newborn’s thyroid function using the standard radiological practices followed in New Zealand [27].

### 2. Methods

We conducted a retrospective cohort analysis of newborns conceived following OSCM HSG in the Auckland region, New Zealand, from 2000 to 2019. TSH data from the newborn metabolic screening programme (NMSP) were extracted and used for the analysis. The cohort was identified from the database of OSCM HSGs kept by a fertility specialist and the radiology practice performing these procedures in the region from the year 2000 onwards. The standard approach for OSCM HSG in Auckland, New Zealand, involved using one ampoule or less of Lipiodol (usually 4–10 ml Lipiodol) during the HSG, which was performed in the follicular phase (between 5th and 12th day of the cycle) [27].

The women who conceived within six months of OSCM HSG were identified, and the TSH information of these babies was obtained from the NMSP. Necessary ethical approvals were obtained for this retrospective study. Confidentiality was maintained by ensuring that only coded data was received by the researchers from the custodians of databases and NMSP. If a child required referral to a paediatric endocrinologist for further assessment or initiation of thyroid hormone therapy, this was also recorded. The flowchart for cohort identification is shown in Figure 1. We included the babies who were confirmed as conceived within six months of HSG (based on the date of HSG, date of delivery, and gestational age) and excluded those who were very low birth weight (VLBW), i.e., those less than 1500 grams at birth, multiple births, or where newborn screening data were not available.

The baseline characteristics of the newborns identified by the NMSP as OSCM offspring (n = 168) are described along with demographics of all babies screened by the NMSP (population comparison) in Table 1. 146 babies were included in the study after exclusion as described in the flowchart in Figure 1.

New Zealand introduced newborn screening for CH in 1981 and adopted a TSH-only screen in 1986. Newborn dried blood spot (DBS) screening employs capillary heel blood collected onto a card and is offered routinely for all children. Most samples are collected between 48 and 72 hours of age with a national coverage of >99% live births. Samples are posted for analysis to the laboratory in Auckland, which is the single facility conducting all newborn TSH tests in the country. The Perkin–Elmer AutoDelfia assay was used during the period of the study to measure whole-blood TSH. Delfia is a solid-phase, two-site immunofluor assay and is based on the direct sandwich technique in which two monoclonal antibodies are directed against two separate antigenic determinants on the TSH molecule. It measures the whole blood and hence has a value approximately 2.2 times that of plasma in a 2-day-old neonate. In the NMSP, there was a change in assay platform from AutoDelfia (AD) to genetic screening processor (GSP) in March 2019, but no significant change in the normal TSH level was noted. TSH levels <15 mIU/L are considered normal by the NMSP [30].

### 3. Outcome

The outcome of the study was the incidence of permanent or transient thyroid dysfunction at birth in the offspring conceived within six months to mothers who had preconceptional OSCM HSG.

### 4. Results

Table 2 shows the TSH distribution of newborns whose TSH data were analysed. As described earlier in Table 1, the group comprised 146 consecutive traceable newborn babies of women who had undergone OSCM HSG in the Auckland region of New Zealand that were not of very low birth weight. This group included 79 female and 67 male infants with birth weights ranging from 1710 to 4660 gm. TSH levels were compared to 27,071 normal screens received from 1 January to 30 June 2020 by the NMSP (after excluding the screening cards from NICU babies, so that the TSH levels are more comparable with the neonates included).
We further grouped these neonates based on the proximity of their conception to OSCM HSG to analyse the effect of presumed higher iodine exposure in those conceived in the immediate months following the HSG. Table 3 shows the distribution of TSH (mean, SD, median, and range) within each group of neonates conceived in a particular time frame following the OSCM HSG.

These data show that all babies had normal TSH levels (well below the cutoff, 15 mIU/L) on the newborn screening. The TSH ranged from 1 to 7 mIU/L on the whole blood

Table 1: Baseline characteristics of newborns conceived following OSCM HSG along with population statistics of normal births in New Zealand.

|                        | Neonates included | Neonates excluded | Normal births (01/01/2020–30/06/2020) |
|------------------------|-------------------|-------------------|-------------------------------------|
| Gender (male/female)   | 146               | 22                | 29573                               |
| <1000 g                | 67/79             | 12/10             | 14989/14312                         |
| 1000–1999 g            | 0                 | 3 (13.6)          | 295 (1.0)                           |
| 2000–2499 g            | 2 (1.4)           | 0                 | 673 (2.4)                           |
| >=2500 g               | 137 (93.8)        | 17 (77.3)         | 1421 (5.0)                          |
| Birthweight average (range) | 3347 (1710–4660) | 3061 (880–4090) | 3372 (495–6090)                     |
| Multiple births        | 0                 | Twins 1 set       | Not known                            |

Numbers may not add to the total as not all demographics are complete.
analysis of DBS using the Perkin–Elmer AutoDelfia assay. The average TSH remained similar irrespective of the time elapsed from HSG to the conception. In addition, the 22 babies of the cohort excluded from analysis also had normal TSH at screening.

5. Discussion

In this retrospective cohort study, we did not identify any cases of CH among 146 newborns conceived following an OSCM HSG over the last 20 years nor did we identify a difference in TSH levels at newborn screening. 76% of these neonates were conceived in the immediate 3 cycles following OSCM HSG to their mothers, and in this group, contrary to our expectation from the previous Japanese data [25], we did not find a higher TSH compared to those conceived in the later cycles.

Table 4 compares our data with previous studies on the effect of preconceptional OSCM HSG on newborn thyroid function.

| Time gap between HSG and conception | Number of neonates conceived within this time frame | Average TSH within the group mean (SD) | Median TSH within the group median (range) |
|-------------------------------------|--------------------------------------------------|--------------------------------------|------------------------------------------|
| 1 month                             | 45                                               | 1.9 (1.3)                            | 2 (1–7)                                 |
| 2 months                            | 45                                               | 1.9 (1.3)                            | 2 (1–7)                                 |
| 3 months                            | 21                                               | 1.9 (0.9)                            | 2 (1–4)                                 |
| 4 months                            | 11                                               | 2.2 (1.0)                            | 2 (1–4)                                 |
| 5 months                            | 16                                               | 2.5 (1.5)                            | 2 (1–6)                                 |
| 6 months                            | 8                                                | 1.8 (1.0)                            | 1 (1–4)                                 |

TSH: thyroid-stimulating hormone.

Table 3: TSH distribution of neonates conceived within various time frames after the OSCM HSG.

| TSH mIU/L blood | Neonates included | Normal births (01/01/2020–30/06/2020) | P value |
|-----------------|-------------------|-------------------------------------|---------|
| n               | %                 | n                                   | %       |         |
| 1               | 65                | 11,360                              | 41.9    | 0.53    |
| 2               | 43                | 7,917                               | 29.2    | 0.96    |
| 3               | 21                | 4,129                               | 15.2    | 0.77    |
| 4               | 12                | 1,806                               | 6.7     | 0.45    |
| 5               | 1                 | 934                                 | 3.4     | 0.06    |
| 6               | 2                 | 431                                 | 1.6     | 0.83    |
| 7               | 2                 | 224                                 | 0.8     | 0.47    |
| 8               | 0                 | 149                                 | 0.6     |         |
| 9               | 0                 | 75                                  | 0.3     |         |
| 10–14           | 0                 | 14                                  | 0.1     |         |
| >15             | 0                 | 32                                  | 0.2     |         |
| Total           | 146               | 27,071                              |         |         |

TSH: thyroid-stimulating hormone.

The strengths of this research are a relatively large sample size and the uniformity of sample analysis. In addition, a TSH-based screening programme was used that identifies transient TSH elevations. The limitations are that potentially relevant information such as OSCM volume and maternal TSH levels were not recorded as this was a retrospective study. Preconceptional OSCM HSG can cause maternal thyroid dysfunction, particularly subclinical hypothyroidism (SCH) as shown in some studies [29, 36, 37]. As the fetus is entirely dependent on the placental transfer of maternal T4 in the first trimester, thyroid dysfunction in the mother during pregnancy including SCH could cause fetal hypothyroidism and subsequently influence the neurocognition.
of the offspring. Another point to note is that the newborn screening assay is not well calibrated at the low end as its purpose is to detect high levels >15mIU/l blood. Therefore, low measurements are not very precise, and there may still be subtle differences in TSH levels that we were unable to demonstrate.

Overall, the results are reassuring, especially for the 90 children conceived in the immediate two cycles following the HSG. Thus, the results of our retrospective analysis suggest that OSCM HSGs do not cause a significant rise in the incidence of neonatal thyroid dysfunction. Further prospective studies are necessary to understand if maternal iodine levels and thyroid function following OSCM HSG influence the offspring’s thyroid status at birth and their long-term neurocognitive outcome.

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethical Approval

This research was approved by the Auckland Health Research Ethics Committee (AHREC) on 15/02/2021. A formal approval was also obtained from the Newborn Metabolic Screening Program committee.

Disclosure

Guerbet had no role in any aspects of the study including study design, recruitment or delivery of the study, manuscript preparation, data interpretation, or decision to publish it.

Conflicts of Interest

This study is funded by an unrestricted institutional grant by Guerbet (manufacturer of Lipiodol) to the Liggins institute, Auckland. NJ has undertaken paid consultancies for Guerbet. PH has received fees for speaking in two webinars sponsored by Guerbet. JP and RS have been paid for presenting and being an advisory board member by Guerbet.

Authors’ Contributions

DMM conducted the analysis and wrote the manuscript. PLH verified the analysis. PLH, JMP, NPJ, RGS, and SO’S conceptualised the study and contributed to the manuscript. JMP and NPJ assisted with the identification of the cohort. NLH and DW assisted with data extraction and contributed to the manuscript. All authors approved the final manuscript.

Acknowledgments

This study was funded by an unrestricted institutional grant by Guerbet to the Liggins Institute, Auckland. This is investigator-initiated research, and the fund was administered by the Liggins Institute which sponsors the study (contact address: Private Bag 92019, Victoria Street, West Auckland 1142, New Zealand).

References

[1] P. van Trotsenburg, A. Stoupa, J. Léger et al., “Congenital hypothyroidism: a 2020-2021 consensus guidelines update-an ENDO-European reference network initiative endorsed by the European society for pediatric endocrinology and the European society for endocrinology,” Thyroid, vol. 31, no. 3, pp. 387–419, 2021.
[2] J. Léger, A. Olivieri, M. Donaldson et al., “European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism,” Hormone Research in Paediatrics, vol. 81, no. 2, pp. 80–103, 2014.
[3] B. B. Albert, N. Heather, J. G. B. Derraik et al., “Neurodevelopmental and body composition outcomes in children with congenital hypothyroidism treated with high-dose initial replacement and close monitoring,” Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 9, pp. 3663–3670, 2013.
[4] B. B. Albert, W. S. Cutfield, D. Webster et al., “Etiology of increasing incidence of congenital hypothyroidism in New Zealand,” Thyroid, vol. 26, no. 1, pp. 113–120, 2016.
A. Ghassabian, J. Steenweg-de Graaff, R. P. Peeters et al., “Maternal urinary iodine concentration in pregnancy and children’s cognition: results from a population-based birth cohort in an iodine-sufficient area,” BMJ Open, vol. 4, no. 6, Article ID e005520, 2014.

K. Mekaru, S. Kamiyama, H. Masamoto, K. Sakamoto, and Y. Aoki, “Thyroid function after hysterosalpingography using an oil-soluble iodinated contrast medium,” Gynecological Endocrinology, vol. 24, no. 9, pp. 498–501, 2008.

S. So, W. Yamaguchi, H. Tajima et al., “The effect of oil and water-soluble contrast medium in hysterosalpingography on thyroid function,” Gynecological Endocrinology, vol. 33, no. 9, pp. 682–685, 2017.